The charts on this page feature a breakdown of the total annual pay for the top executives at NAVIDEA BIOPHARMACEUTICALS as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. NAVIDEA BIOPHARMACEUTICALS income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. NAVIDEA BIOPHARMACEUTICALS annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Jed A. Latkin
Former Chief Executive Officer, Chief Operating Officer and Chief Financial Officer
Total Cash $408,333 Equity $187,849 Other $750,908 Total Compensation $1,347,090
Michael S. Rosol Ph.D.
Chief Medical Officer (Principal Executive Officer)
Total Cash $326,583 Equity $133,037 Other $9,731 Total Compensation $469,351
Joel H. Kaufman
Former Chief Business Officer
Total Cash $81,458 Equity $46,962 Other $18,845 Total Compensation $147,265
Michel Mikhail Ph.D.
Chief Regulatory Officer
Total Cash $71,303 Equity $81,580 Other $167 Total Compensation $153,050
Erika L. Eves
Vice President, Finance & Administration
Total Cash $200,686 Equity $23,481 Other $12,563 Total Compensation $236,730
For its 2019 fiscal year, NAVIDEA BIOPHARMACEUTICALS, listed the following board members on its annual proxy statement to the SEC.
Adam D. Cutler Total Cash $81,803
Claudine Bruck, Ph.D. Total Cash $71,847
S. Kathryn Rouan, Ph.D. Total Cash $71,803
Y. Michael Rice Total Cash $96,847

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.